| Market Cap | ₹18,459Cr |
| ROE | 7.25% |
| P/E Ratio(TTM) | 38.91 |
| EPS(TTM) | 29.78 |
| P/B Ratio | 2.80 |
| Dividend Yield | 0.43% |
| Industry P/E | 33.43 |
| Book Value | 413.79 |
| Debt to Equity | 0.44 |
| Face Value | 1 |
| Parent Organisation | Jubilant Pharmova Limited |
| Managing Director | Mr. Arjun Bhartia |
| NSE Symbol | JUBLPHARMA |
| FUND NAME | AUM(%) |
|---|---|
| Bandhan Focused Fund Direct Growth | 4.19% |
| Kotak Contra Fund Direct Growth | 1.29% |
| Bandhan Small Cap Fund Direct Growth | 1.10% |
| Quant Small Cap Fund Direct Plan Growth | 1.06% |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| Divi's Laboratories | NA (0.00%) | 69.69 | ||
| Neuland Laboratories | NA (0.00%) | 92.72 | ||
| Acutaas Chemicals | NA (0.00%) | 62.04 | ||
| Gujarat Themis Biosyn | NA (0.00%) | 101.08 |